Deferiprone
As of the edition of 20 October 2026, Deferiprone is a small molecule: marketed, first approved in 1999 (EU); US protection ends in 2028.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2011
- Kind
- Small molecule
- Brand name
- Ferriprox
- First approved
- 25 August 1999 (EU)
- Approvals on record
- 8 in 3 regions
- Holder of the most recent approval
- CHIESI FARMACĂUTICA LTDA; 3 holders in all
- Registered trials
- 46, 5 stopped early
- Disease areas
- Inherited and neonatal; Blood and lymph; Nutrition and metabolism; Nervous system; Heart and blood vessels; Urinary and reproductive
US protection
US protection ends in 2028.
The last listed US exclusivity ends in 2028. The application that gives this date is held by Chiesi.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product15 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 15 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 3 | 0 | 0 |
| Phase 1 | 7 | 7 | 0 | 0 |
| Phase 2 | 17 | 12 | 2 | 2 |
| Phase 3 | 8 | 6 | 0 | 1 |
| Phase 4 | 9 | 6 | 0 | 2 |
| All trials | 46 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Chiesi Farmaceutici | Applicant | 1999 to now |
| ApoPharma | Applicant and Lead sponsor of trials | 2002 to now |
| Chiesi | Acquired holder | 2020 to now |